Serum Antibodies to Lipophilin B Detected in Late Stage Breast Cancer Patients

• Published in: Clinical cancer research Vol. 9; no. 2; pp. 749 - 754
• Main Authors: CARTER, Darrick, DILLON, Davin C, PERSING, David H, HOUGHTON, Raymond L, REYNOLDS, Lisa D, RETTER, Marc W, FANGER, Gary, MOLESH, David A, SLEATH, Paul R, MCNEILL, Patricia D, VEDVICK, Thomas S, REED, Steven G
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.02.2003
• Subjects: Amino Acid Sequence; Antibodies - blood; Antibody Specificity; Biological and medical sciences; Breast Neoplasms - blood; Breast Neoplasms - immunology; Breast Neoplasms - pathology; Carrier Proteins - chemistry; Carrier Proteins - genetics; Carrier Proteins - immunology; Disease Progression; Endometrial Neoplasms - blood; Endometrial Neoplasms - immunology; Female; Globins - chemistry; Globins - genetics; Globins - immunology; Gynecology. Andrology. Obstetrics; Humans; Lung Neoplasms - blood; Lung Neoplasms - immunology; Male; Mammary gland diseases; Medical sciences; Molecular Sequence Data; Myelin Proteins; Neoplasm Staging; Ovarian Neoplasms - blood; Ovarian Neoplasms - immunology; Peptide Fragments - chemical synthesis; Peptide Fragments - chemistry; Prostatic Neoplasms - blood; Prostatic Neoplasms - immunology; Proteolipids; Reference Values; Secretoglobins; Transcription, Genetic; Tumors; Uteroglobin; Human; Biological fluid; Immune response; Tumor associated antigen; Antibody; Malignant tumor; Mammary gland diseases; Female; Advanced stage; Serum; Diagnosis; Mammary gland; Lipophilin; Humoral immunity
• ISSN: 1078-0432; 1557-3265

Lipophilin B mRNA is overexpressed in ∼70% of breast tumors and shows a high degree of correlation with the mRNA expression profile of mammaglobin. This is further supported by the recent finding that, like other members of the secretoglobulin–uteroglobin family, mammaglobin and lipophilin B form a heteroduplex. The studies described show that there are pre-existing antibodies to lipophilin B peptide in the sera of breast cancer patients with different stages and grade of tumor and that this response is different from that seen to recombinant mammaglobin and native mammaglobin–lipophilin B complex. The highest titers were observed in later stage tumors. In addition, low levels of antibody were also seen in some patients with prostate and ovarian cancers, consistent with lipophilin B mRNA expression in these tumors at lower abundance than in breast tumors. In contrast, lipophilin B antibodies were absent in 20 healthy donor sera and 30 lung cancer sera. A polymorphism identified in Lipophilin B did not appear to influence human sera reactivity. The data indicate that humoral immune responses to lipophilin B may serve as a diagnostic indicator, particularly for breast cancer.